Cargando…

Mimicking Hypoxia to Treat Anemia: HIF-Stabilizer BAY 85-3934 (Molidustat) Stimulates Erythropoietin Production without Hypertensive Effects

Oxygen sensing by hypoxia-inducible factor prolyl hydroxylases (HIF-PHs) is the dominant regulatory mechanism of erythropoietin (EPO) expression. In chronic kidney disease (CKD), impaired EPO expression causes anemia, which can be treated by supplementation with recombinant human EPO (rhEPO). Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flamme, Ingo, Oehme, Felix, Ellinghaus, Peter, Jeske, Mario, Keldenich, Jörg, Thuss, Uwe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230943/ https://www.ncbi.nlm.nih.gov/pubmed/25392999 http://dx.doi.org/10.1371/journal.pone.0111838

Ejemplares similares

Discovery of Molidustat (BAY 85‐3934): A Small‐Molecule Oral HIF‐Prolyl Hydroxylase (HIF‐PH) Inhibitor for the Treatment of Renal Anemia
por: Beck, Hartmut, et al.
Publicado: (2018)

Absorption, distribution, metabolism and excretion of molidustat in healthy participants
por: Lentini, Silvia, et al.
Publicado: (2020)

Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis
por: Akizawa, Tadao, et al.
Publicado: (2021)

FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase
por: Flamme, Ingo, et al.
Publicado: (2017)

Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single‐arm, phase 3 study
por: Akizawa, Tadao, et al.
Publicado: (2021)

Structural Basis of Prolyl Hydroxylase Domain Inhibition by Molidustat
por: Figg, William D., et al.
Publicado: (2021)

BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I
por: Ellinghaus, Peter, et al.
Publicado: (2013)

Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single‐arm, open‐label, phase 3 study
por: Akizawa, Tadao, et al.
Publicado: (2021)

Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials
por: Yamamoto, Hiroyasu, et al.
Publicado: (2023)

Drug‐drug interaction of atazanavir on UGT1A1‐mediated glucuronidation of molidustat in human
por: van der Mey, Dorina, et al.
Publicado: (2020)

miR-3934 regulates the apoptosis and secretion of inflammatory cytokines of basophils via targeting RAGE in asthma
por: Dou, Liyan, et al.
Publicado: (2022)

Downregulation of miR-3934 in Peripheral Blood Mononuclear Cells of Asthmatic Patients and Its Potential Diagnostic Value
por: Wang, Wenyu, et al.
Publicado: (2021)

Comparison of Oral Recombinant Erythropoietin and Subcutaneous Recombinant Erythropoietin in Prevention of Anemia of Prematurity
por: Saeidi, R, et al.
Publicado: (2012)

Erythropoietin and Cancer: The Unintended Consequences of Anemia Correction
por: Debeljak, Nataša, et al.
Publicado: (2014)

Treatment of Anemia in Kidney Disease: Beyond Erythropoietin
por: Wish, Jay B.
Publicado: (2021)

HIF-stabilizing biomaterials: from hypoxia-mimicking to hypoxia-inducing
por: Colombani, Thibault, et al.
Publicado: (2023)

Erythropoietin in the intensive care unit: beyond treatment of anemia
por: Patel, Nimesh SA, et al.
Publicado: (2011)

Cost-effectiveness of continuous erythropoietin receptor activator in anemia
por: Schmid, Holger
Publicado: (2014)

Erythropoietin Levels in Elderly Patients with Anemia of Unknown Etiology
por: Gowanlock, Zachary, et al.
Publicado: (2016)

Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin
por: Hanna, Ramy M., et al.
Publicado: (2020)

Erythropoietin in bone homeostasis—Implications for efficacious anemia therapy
por: Lappin, Katrina M., et al.
Publicado: (2021)

Serum Erythropoietin level in anemia of elderly with unclear etiology
por: Seong, Ju Yong, et al.
Publicado: (2023)

Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies
por: Akizawa, Tadao, et al.
Publicado: (2019)

Downregulation of miR-3934-5p enhances A549 cell sensitivity to cisplatin by targeting TP53INP1
por: Ren, Aijun, et al.
Publicado: (2019)

Downregulation of microRNA-3934-5p induces apoptosis and inhibits the proliferation of neuroblastoma cells by targeting TP53INP1
por: Ye, Wei, et al.
Publicado: (2019)

Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies
por: Yamamoto, Hiroyasu, et al.
Publicado: (2019)

Scaling Pharmacodynamics from Rats to Humans to Support Erythropoietin and Romiplostim Combination Therapy to Treat Erythropoietin-Resistant Anemia
por: Fan, Xiaoqing, et al.
Publicado: (2023)

Anemia and blood transfusion in the critically ill patient: role of erythropoietin
por: Corwin, Howard L
Publicado: (2004)

Erythropoietin stimulating agents in the management of anemia of chronic kidney disease
por: Hayat, Amir, et al.
Publicado: (2008)

The Levels of Hepcidin and Erythropoietin in Pregnant Women with Anemia of Various Geneses
por: Vazenmiller, Dmitriy, et al.
Publicado: (2018)

“Ideal” parathyroid hormone in erythropoietin‐stimulating agents‐resistant anemia
por: Ashraf, Bilal, et al.
Publicado: (2021)

First‐in‐human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics
por: Klein, Stefan, et al.
Publicado: (2022)

Heart failure-associated anemia: bone marrow dysfunction and response to erythropoietin
por: Ruifrok, Willem-Peter T., et al.
Publicado: (2010)

Tubular immaturity causes erythropoietin-deficiency anemia of prematurity in preterm neonates
por: Asada, Nariaki
Publicado: (2018)

Myelofibrosis-Induced Erythropoietin-Resistant Anemia Due to Severe Refractory Hyperparathyroidism
por: Sethi, Sidharth Kumar, et al.
Publicado: (2018)

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state
por: Joharapurkar, Amit A., et al.
Publicado: (2022)

Gut Microbiota Correlates With Clinical Responsiveness to Erythropoietin in Hemodialysis Patients With Anemia
por: Zhu, Yifan, et al.
Publicado: (2022)

Serum levels of erythropoietin in patients with chronic obstructive pulmonary disease and anemia
por: Rezvani, Alireza, et al.
Publicado: (2023)

Acute Vhl Gene Inactivation Induces Cardiac HIF-Dependent Erythropoietin Gene Expression
por: Miró-Murillo, Marta, et al.
Publicado: (2011)

Methylation impact analysis of erythropoietin (EPO) Gene to hypoxia inducible factor-1α (HIF-1α) activity
por: Dewi, Firli Rahmah Primula, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8spuqcut6jek0a06o8tis8o8p0